WESTCHESTER COUNTY BIOSCIENCES UPDATE
Featuring news, events and industry trends
Applications Close October 25:
Westchester County Biosciences Accelerator

Interested in launching a bioscience venture?

The Westchester County Biosciences Accelerator is a competitive entry, 6-month long program designed to provide entrepreneurship education and regional networking to seed-stage ventures preparing to build their teams and secure funds. Innovators with therapeutics, diagnostics, medical devices, research tools, digital health and materials technology breakthroughs are invited to apply. You do not need to have already formed a company to apply.
Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

Purchase-based, Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina announced the pricing of its upsized initial public offering of 3,768,116 shares of its common stock at a public offering price of $12.00 per share.

Cognition’s common stock has been approved for listing on The Nasdaq Global Market under the symbol “CGTX.”
Nutrition21 to Share Latest Research on Branded Ingredients for Healthy Aging and Beauty at SupplySide West 2021

Harrison-based Nutrition21 will share its latest research on its new proprietary healthy-aging ingredient, Lustriva, plus recent research on esports and other branded ingredients, at the upcoming SupplySide West trade show in Las Vegas.
Lustriva is a new ingredient launched this past February for the healthy-aging market. It is a patented complex of bonded arginine silicate and magnesium biotinate whose form of biotin is 40 times more soluble than D-biotin. The ingredient has been shown to increase hair growth, reduce facial wrinkles and fine lines, and improve skin texture.
The company will also highlight its latest research on esports ingredient NooLVL, which is a patented complex of bonded arginine silicate and an optimized dose of inositol, plus new research on its ingredient Velositol. Velositol helps increase muscle protein synthesis (MPS). When paired with whey protein, plant protein, or branched chain amino acids, Velositol can help amplify MPS benefits.
Teladoc Health Reimagines Primary Care with Primary360

Purchase-based Teladoc Health, the global leader in whole-person virtual care, announced that its primary care service, Primary360, is now available to commercial health plans, employers and other organizations that sponsor health care for individuals and families in the United States. Primary360 solves persistent challenges in access to high quality health care for millions of individuals, especially those who do not have an ongoing relationship with a primary care provider.  
 
Teladoc Health has received a positive initial response to Primary360 in the marketplace and the role it plays in delivering comprehensive, virtual-first benefits. Several Fortune 1000 employers are live today on the new primary care service, with other large employers and health plans such as Aetna launching nationwide in early 2022.
Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program
 
Sapience Therapeutics, Inc., a biotechnology company in Harrison focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it was awarded a Small Business Innovative Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to establish proof-of-concept for the use of its second clinical candidate, ST316, to treat Wnt/β-catenin-dependent breast cancer.
 
This grant was supported by the National Cancer Institute of the National Institutes of Health under Award Number R43CA265503. 

Have good news to share from
Westchester’s biosciences ecosystem?

Please let us know.

If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.